Grant: Master's Award: Canada Graduate Research Scholarships - Master's program
University of Ottawa
$27,000.00
HOXA5/Galectin1 signalling in Glioblastoma
FY 2025-26
Summary
Glioblastoma (GB) is the most aggressive primary brain cancer in adults with an extremely high mortality rate. GB diagnosis is characterized by tumour heterogeneity, therapeutic resistance, and high tumour recurrence rate. Available treatments are limited, therefore tumour recurrence rate is exceedingly high and therapeutic resistance is a frequent occurrence in patients. Brain tumour stem cells (BTSCs) are a population of brain tumour cells that are responsible for GB tumour heterogeneity and therapeutic resistance. GB is characterized by dysregulated developmental signalling pathways and aberrant transcription factor (TF) activity, implicating the role of transcriptomic regulation in GB prognosis and mechanistic progression. Unfortunately, the exact mechanistic progression enabling the transition from BTSCs to glioblastoma remains unknown. Past studies have attempted to manipulate developmental signalling pathways individually and were met with little success. Our lab discovered that lactose binding lectin Galectin1 and TF Homeobox A-5 (HOXA5) complex together, and bind downstream genes that control key determinants of GB progression: self-renewal, proliferation, and irradiation resistance. My project aims to further investigate the regulatory role of HOXA5/Galectin1 on the transcriptomic environment of BTSCs by uncovering the network of HOXA5/Galectin1 protein and DNA candidate interactors, and the consequences of these interactions. Elucidating the transcriptomic environment of GB by identifying transcriptomic regulatory components involved in the HOXA5/Galectin1 axis will enable us to better exploit potential vulnerabilities in BTSCs, develop efficient GB therapies, and vastly improve patient quality of life and survival rate.
Department
Program
Master's Award: Canada Graduate Research Scholarships - Master's program
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
573179
Name
Cruz Julianne Bianca P
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
HOXA5/Galectin1 signalling in Glioblastoma
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Brain Tumour Stem Cells; Developmental Signalling Pathways; Galectin1; Glioblastoma; Homeobox Genes; Neuro-Oncology; Stemness; Transcription Factors; Transcriptome
Abstract
Glioblastoma (GB) is the most aggressive primary brain cancer in adults with an extremely high mortality rate. GB diagnosis is characterized by tumour heterogeneity, therapeutic resistance, and high tumour recurrence rate. Available treatments are limited, therefore tumour recurrence rate is exceedingly high and therapeutic resistance is a frequent occurrence in patients. Brain tumour stem cells (BTSCs) are a population of brain tumour cells that are responsible for GB tumour heterogeneity and therapeutic resistance. GB is characterized by dysregulated developmental signalling pathways and aberrant transcription factor (TF) activity, implicating the role of transcriptomic regulation in GB prognosis and mechanistic progression. Unfortunately, the exact mechanistic progression enabling the transition from BTSCs to glioblastoma remains unknown. Past studies have attempted to manipulate developmental signalling pathways individually and were met with little success. Our lab discovered that lactose binding lectin Galectin1 and TF Homeobox A-5 (HOXA5) complex together, and bind downstream genes that control key determinants of GB progression: self-renewal, proliferation, and irradiation resistance. My project aims to further investigate the regulatory role of HOXA5/Galectin1 on the transcriptomic environment of BTSCs by uncovering the network of HOXA5/Galectin1 protein and DNA candidate interactors, and the consequences of these interactions. Elucidating the transcriptomic environment of GB by identifying transcriptomic regulatory components involved in the HOXA5/Galectin1 axis will enable us to better exploit potential vulnerabilities in BTSCs, develop efficient GB therapies, and vastly improve patient quality of life and survival rate.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Cruz, Julianne Bianca P
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~